2. Dendritic cells as regulators of immunity and tolerance - 12/08/11
This activity is available for CME credit. See page 5A for important information.
Abstract |
Dendritic cells (DCs) are antigen sampling sentinels of the peripheral tissue and specialists for antigen capture, processing, and presentation to T cells as well as T-cell priming. By virtue of their mission as antigen samplers, they populate the body surfaces that line the border of our organism with the environment such as the skin and the mucosa of the respiratory and the gastrointestinal tract. Although all DCs share some classic features, their individual organ-specific phenotype and function are ascertained by a complex, dynamic network of coregulatory factors provided by their microenvironment. DC subtypes might initiate novel inflammatory immune responses as well as accelerate or break down ongoing inflammatory immune reactions in the skin, the gut, and the respiratory tract. On the basis of the recognition of self-signals or nonself-signals in the presence or absence of danger signals, the interplay of DC antigen uptake and presentation leads into immunosilencing or immunoactivating properties, which designate the outcome of tolerance or defensive immunity within the skin, the gut, or the respiratory tree.
Le texte complet de cet article est disponible en PDF.Key words : Dendritic cells, immunity, tolerance, skin, mucosa
Abbreviations used : DC, ICOS-L, IDEC, LC, PDC
Plan
Supported by grants from the German Research Council (DFG NO454/1-4, DFG NO454/2-3, SFB 704 TPA4 and TPA15), a Bonne Forschungsförderung grant of the University of Bonn, and partly by National Institutes of Health/National Institute of Allergy and Infectious Diseases contract N01AI40029. N.N. is supported by a Heisenberg-Fellowship of the Deutsche Forschungsgemeinschaft NO454/3-1. |
|
Disclosure of potential conflict of interest: N. Novak has received grants from the German Research Council, Bencard, and LETI Pharma and is on the Novartis advisory board. T. Bieber has consultant arrangements with Novartis, Intendis, and Astellas and has received grants/research support from Stallergenes. |
Vol 121 - N° 2S2
P. S370-S374 - février 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?